Ionis

Congrats to Dr. Tim Miller of Washington University on receiving the Potamkin Prize for his work validating MAPT as an ASO target. It was an honor to collaborate on this breakthrough in neurodegenerative disease research.

Today’s data reflect our ongoing commitment to developing RNA‑targeted medicines that may help people living with Alexander disease. We are deeply grateful to the patients, families, investigators and broader community who have made this research possible. bit.ly/4tqAm9l

Today, we announced additional positive results from the pivotal study of our investigational medicine for Alexander disease (AxD). Read more: bit.ly/4tqAm9l $IONS

Headed to the 2026 #AANAM? Make sure to stop by booth 1824 to meet some of our amazing Ionis team members and learn about our latest innovations in #neurology. $IONS

Save the date for our Q1 2026 earnings webcast. Register now and tune in live on April 29 at 8:30 am ET: bit.ly/4dKqZMF $IONS

With National Triglycerides Day on 3/28, we are reminded of the importance of continued education and innovation for people living with severe hypertriglyceridemia (sHTG). We look forward to connecting at @ACCinTouch Scientific Sessions. HCPs, learn more: bit.ly/3PjZI9J

This #AmyloidosisAwarenessMonth, learn about Charles’ unique perspective as a retired cardiologist on what it’s like to live with transthyretin amyloid cardiomyopathy (ATTR-CM). Read more: bit.ly/4t6duLC

We are pleased to announce that the U.S. FDA has accepted for Priority Review our New Drug Application (NDA) for our investigational Alexander disease (AxD) treatment. Read more here: bit.ly/4rU3Yu7 $IONS

Today we announced changes to our Board of Directors. Read the full press release: bit.ly/4liWyP9

On #RareDiseaseDay, we honor the strength, courage and resilience of the patients, families, caregivers, researchers and clinicians who make up the rare disease community. We are proud to work with you and learn from you every step of the way. #ShowYourStripes

At the @AAAAI 2026 Annual Meeting, we’ll be sharing new data supporting our RNA-targeted prophylactic medicine for hereditary angioedema (#HAE) across eight presentations. Learn more: bit.ly/4baHAr4 #RareDisease #AAAAI2026

The U.S. FDA has accepted for Priority Review our supplemental New Drug Application (sNDA) for our investigational severe hypertriglyceridemia (sHTG) treatment. More details here: bit.ly/4ueJnmL $IONS

Today we reported Q4 and full year 2025 financial results. Read more about our updates and tune in live to the webcast today at 8:30 AM ET to hear our fourth quarter and full year highlights: bit.ly/4rELKgS $IONS

Our CSO, Frank Bennett, joins @anirvan0419 on a new episode of #LetsTalkAboutThat – a podcast that explores the ideas, people & events shaping the world. Tune in to learn about Frank’s career, the power of RNA-targeted tech & the future of our medicines: bit.ly/40efhSB

Only 10 days to go until #RareDiseaseDay!  #ShowYourStripes and join us to raise awareness and help amplify the voices of the more than 350 million people worldwide living with rare diseases. We hear you, we see you and we stand with you. #MoreThanYouCanImagine $IONS

On International Angelman Day, we recognize the strength, resilience and joy of this community. To learn more about #Angelmansyndrome, watch our @balancingacttv Behind the Mystery of Angelman syndrome episode on our website: bit.ly/4afZYhY $IONS

Save the date for our Q4 and full year 2025 earnings webcast. Register now and tune in live on February 25 at 11:30 am ET: bit.ly/4qtnIUo $IONS

High triglycerides associated with severe hypertriglyceridemia (sHTG) increase the risk for acute pancreatitis. In people with a history of acute pancreatitis, the risk of future attacks is even greater. HCPs, learn more: bit.ly/42SWlug

We are excited to announce that Ionis’ and Otsuka Pharmaceutical Co., Ltd.’s prophylactic treatment for hereditary angioedema (#HAE) has been approved in Europe. Learn more: bit.ly/3LYkUk5 $IONS

At #JPM26, we painted a bold picture of a catalyst-rich year ahead for Ionis. Curious about what’s to come? Hear from our CEO, Brett P. Monia PhD, about the upcoming year by the numbers: ionis.com/newsroom/defin…